特应性皮炎患者接种新型冠状病毒疫苗的建议及依据  

Recommendations and Evidence for COVID-19 Vaccine in Patients with Atopic Dermatitis

作　　者：朱昱彦 杨倩文 何霞 韩珂[1] 吴竞鲜 解春宝 李素萍[5] 沈金翠[6] 李文渊[2,3] 王玥媛 易小清 边原 苟梦秋 朱昶宇[1,2,3] 童荣生 ZHU Yuyan;YANG Qianwen;HE Xia;HAN Ke;WU Jingxian;XIE Chunbao;LI Suping;SHEN Jincui;LI Wenyuan;WANG Yueyuan;YI Xiaoqing;BIAN Yuan;GOU Mengqiu;ZHU Changyu;TONG Rongsheng(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;Dept.of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,Chengdu 610072,China;School of Medicine/Sichuan Provincial Key Laboratory of Individualized Drug Therapy,University of Electronic Science and Technology of China,Chengdu 610072,China;Dept.of Clinical Laboratory,Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,Chengdu 610072,China;Dept.of Neurology,Sichuan Academy of Medical Sciences&Sichuan Provincial People’s Hospital,Chengdu 610072,China;Dept.of Dermatology,Chengdu Second People’s Hospital,Chengdu 610017,China)

机构地区：[1]电子科技大学医学院,成都610072 [2]四川省医学科学院·四川省人民医院药学部,成都610072 [3]电子科技大学医学院/个体化药物治疗四川省重点实验室,成都610072 [4]四川省医学科学院·四川省人民医院检验科,成都610072 [5]四川省医学科学院·四川省人民医院神经内科,成都610072 [6]成都市第二人民医院皮肤科,成都610017

出　　处：《中国医院用药评价与分析》2022年第12期1526-1529,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家重点研发计划重点专项(No.2020YFC2005500);四川省科技厅重点研发项目(No.2019FS0514、2022YFS0272);四川省医学科学院·四川省人民医院科研基金项目(No.2020LY06);个体化药物治疗四川省重点实验室开放课题资助项目(No.2021ZD02)。

摘　　要：新型冠状病毒为新型冠状病毒感染的病因,疫苗接种可起到有效的防控作用。然而,部分特定人群尤其是慢性疾病和免疫紊乱的患者,对新型冠状病毒疫苗的接种持观望态度,即疫苗犹豫。特应性皮炎(AD)是一类与免疫紊乱相关的慢性炎症性皮肤病,目前没有明确的指南说明AD患者是否应该接种新型冠状病毒疫苗。本文整理了新型冠状病毒疫苗与AD患者症状间的交集,结合国内外AD患者接种疫苗的相关建议,以及对AD患者接种新型冠状病毒疫苗的回顾性调研,针对AD患者是否应该接种新型冠状病毒疫苗提出建议,旨在为医务工作人员和相关研究人员提供参考。SARS-CoV-2 is responsible for the novel coronavirus infection pandemic, and vaccination is an effective precaution against it. However, due to vaccine hesitancy, certain groups of people, especially those with chronic diseases and immune disorders, are on the fence about novel coronavirus vaccination. Atopic dermatitis(AD) is a chronic inflammatory skin disease associated with immune disorders, and there are no clear guidelines on whether patients with AD should be vaccinated with the COVID-19 vaccine. In this paper, the intersection of COVID-19 vaccine on AD patients’ symptoms will be sorted out, and the issue of whether AD patients should be vaccinated with COVID-19 vaccine will be discussed in combination with the relevant recommendations on AD patients’ vaccination at home and abroad, as well as the retrospective investigation of AD patients’ vaccination with COVID-19 vaccine, to provide a reference for medical staff and relevant researchers.

关 键 词：新型冠状病毒 特应性皮炎 新型冠状病毒疫苗 疫苗接种 

分 类 号：R186[医药卫生—流行病学]